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Stroke refers to a variety of conditions caused by the occlusion or hemorrhage of blood
vessels supplying the brain, which is one of the main causes of death and the leading
cause of disability worldwide. In the last years, cell-based therapies have been proposed
as a new approach to ameliorate post-stroke deficits. However, the most appropriate
type of cell to be used in such therapies, as well as their sources, remains a matter
of intense research. A good candidate cell should, in principle, display high plasticity to
generate diverse types of neurons and, at the same time, low risk to cause undesired
outcomes, such as malignant transformation. Recently, a new approach grounded on
the reprogramming of endogenous astrocytes toward neuronal fates emerged as an
alternative to restore neurological functions in several central nervous system diseases.
In this perspective, we review data about the potential of astrocytes to become functional
neurons following expression of neurogenic genes and discuss the potential benefits and
risks of reprogramming astrocytes in the glial scar to replace neurons lost after stroke.
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BACKGROUND
Ischemic insults result in a severe loss of neural cells in the core
of the lesion and variable effects in the surrounding area, com-
monly described as ischemic penumbra. While cell death occurs
during the first hours after interruption of blood supply within
the core of the ischemic lesion, tissue damage in the surrounding
regions is a delayed process, involving several physiopathological
events, such as inflammation and immune response (for a review
see Doyle et al., 2008). Treatments aiming to increase neuronal
survival after stroke are usually limited to the area of penum-
bra and their success in promoting functional recovery is largely
dependent on the extension of the core ischemic area (Goldstein,
2007). Currently, the only treatment available to reduce the size
of the ischemic area is the use of recombinant tissue plasminogen
activator (t-PA) (The National Institute of Neurological Disorders
and Stroke rt-PA Stroke Study Group, 1995), which is approved to
be administered within 3 h after the onset of ischemia (Goldstein,
2007). This narrow time window as well as a number of con-
traindications for t-PA therapymakes such treatment accessible to
an extremely low number of stroke victims (Katzan et al., 2000),
boosting the necessity to develop new strategies to treat stroke
patients.
In the last years, cell-based therapies have been proposed as a
new approach to ameliorate post stroke deficits. Different from
t-PA, cell-based therapies could, in principle, be administered at
any time following the ischemic event and contribute to replace
neurons lost after ischemia and presumably restore neurological
functions (Lindvall and Kokaia, 2011). Chiefly, two main types
of intervention have been proposed: (1) transplantation of exoge-
nous cells (Benchoua and Onteniente, 2011; Lindvall and Kokaia,
2011); and (2) mobilization of endogenous stem or progenitor
cells (Leker et al., 2009; Lindvall and Kokaia, 2011). Both strate-
gies have been shown to promote some degree of improvement in
animal models of stroke (Lindvall and Kokaia, 2004, 2006). Yet,
important limitations regarding the number of neurons replaced,
specification of these neurons into the appropriate neurochemical
subtypes, integration to the preexisting circuitry and potential
side effects hamper the translation into clinical practice of such
therapies.
Amongst the potential side effects, the most feared is the gen-
eration of tumors. In fact, it has been shown that both stem cell
transplantation and stimulation of endogenous neural stem cell
proliferation can lead to tumor formation in rodents and humans
(Doetsch et al., 2002; Erdo et al., 2003; Amariglio et al., 2009).
Therefore, the development of new strategies to replace neurons
following stroke circumventing the limitations and risks discussed
above is imperative tomove cell-based therapies into clinic. In this
scenario, we put in perspective the potential of a new approach
grounded on the reprogramming of local astrocytes into neurons.
ASTROGLIAL CELLS IN THE ADULT BRAIN POSSESS
NEUROGENIC POTENTIAL
Contrary to the previous notion that neurons were not gener-
ated in the mammalian brain after birth, in the last two decades
two neurogenic regions in the adult mammalian brain have been
uncovered: the subependymal zone (SEZ), located along the lat-
eral walls of the lateral ventricles, which holds a population of
astroglial neural stem cells (ANSC) that constantly supply the
olfactory bulb with interneurons (Kriegstein and Alvarez-Buylla,
2009); and the subgranular zone (SGZ) of the hippocampus,
which also contains a population of ANSC capable of generat-
ing neurons to the dentate gyrus throughout life (Gage, 2000).
Besides the significance of these findings to our understanding
of brain physiology (Lledo et al., 2006), they also opened a new
and promising avenue to brain repair after damage (Lindvall and
Kokaia, 2006).
In fact, it has been shown that global and focal ischemic
injuries in rodents lead to a significant increase in the number
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of neurons generate from ANSC both in the SGZ and the SEZ
(Liu et al., 1998; Kee et al., 2001; Arvidsson et al., 2002; Parent
et al., 2002). Some of these newly generate neurons change
their route of migration and roam to lesioned areas after focal
ischemia, where they acquire some characteristics of local neurons
(Arvidsson et al., 2002; Parent et al., 2002). However, survival of
these neurons in the lesioned areas is extremely poor, suggesting
that some survival signal might be missing in re-routed neurons,
leading to their premature death. As mentioned before, treat-
ments with growth factors, used to increase the generation and
survival of newborn neurons from endogenous neural stem cells
(Leker et al., 2009), have also been related with glioma formation
(Doetsch et al., 2002), making such approaches unsafe. Moreover,
it remains to be shown whether such approach could be of any use
in humans, given the great distance that newly generated neurons
would need to transverse to reach the lesioned cortical tissue as
compared to the rodent brain. Last but not least, the functionality
of therapies aiming to recruit neurons from endogenous neuro-
genic niches relies on the occurrence of neurogenesis in the adult
human brain, what has not been observed under physiological
conditions (Sanai et al., 2004, 2011).
More recently, astrocytes of the cortical parenchyma, another
population of astroglial cells, were suggested as an alternative
source for neuronal replacement in neurological diseases (Robel
et al., 2011). Compared to ANSC residing in neurogenic compart-
ments, cortical astrocytes would have four main advantages: (1)
they are located within the lesioned site, eliminating the need of
relocation; (2) their amount is significantly increased after stroke
(Buffo et al., 2008), generating a large amount of exploitable cells;
(3) they can be efficiently reprogrammed into neurons using sim-
ple molecular manipulations (Berninger et al., 2007; Heinrich
et al., 2010; Blum et al., 2011); and (4) they are involved in the
formation of the glial scar, which contributes to generate an anti-
neurogenic environment (Pekny and Nilsson, 2005). Therefore,
astrocyte reprogramming could provide at once a source of new
neurons in large numbers to replace the circuitry lost after stroke
and reduce some negative effects of the glial scar (see below).
EFFICIENT REPROGRAMMING OF ASTROCYTES INTO
GLUTAMATERGIC AND GABAergic NEURONS
Astrocytes isolated from rodent postnatal brain are highly sus-
ceptible to neuronal reprogramming following forced expression
of a single neurogenic fate determinant, such as Neurogenin 2
(NEUROG2), Distal-less homeobox 2 (DLX2), or Achaete-scute
homolog 1 (ASCLl1, also known as MASH1) (Berninger et al.,
2007; Heinrich et al., 2010; Blum et al., 2011). Interestingly,
expression of NEUROG2 induces a glutamatergic phenotype
whereas the expression of MASH1 and DLX2 induces a
GABAergic phenotype, resembling the roles of those transcrip-
tion factors (TFs) in the developing forebrain (Guillemot, 2005).
Astrocytes can not only be reprogrammed into neurons of spe-
cific subtypes but also acquire electrical properties compatible
with a mature neuronal phenotype, such as intrinsic excitability
and the ability to generate action potentials and synaptic contacts
(Berninger et al., 2007; Heinrich et al., 2010).
Reprogramming of postnatal astrocytes using neuro-
genic TFs is a highly efficient process. Approximately, 70%
of NEUROG2-transduced astrocytes differentiated into
βIII tubulin-positive neurons after 7–10 days (Figure 1;
Berninger et al., 2007; Heinrich et al., 2010). By 2–3 weeks
post-transduction, reprogrammed neurons acquire MAP2
immunoreactivity, indicative for dendritic maturation, and
express the vesicular glutamate transporter 1 (VGLUT1), present
in synaptic vesicles within presynaptic terminals of glutamatergic
neurons (Heinrich et al., 2010). Thus, astrocytes reprogrammed
by forced expression of a single TF (NEUROG2) adopt a full
neuronal glutamatergic phenotype forming presynaptic spe-
cializations. Indeed, electrophysiological recordings of neurons
reprogrammed from astrocytes with NEUROG2 demonstrated
both autaptic and synaptic currents that were blocked by CNQX
(an AMPA/kainate glutamate receptor antagonist), further
confirming the glutamatergic nature of the reprogrammed
neurons. Amongst all NEUROG2-transduced astrocyte-derived
neurons recorded, ∼60% exhibited either glutamatergic autaptic
connections onto themselves or glutamatergic synapses onto
nearby neurons (Heinrich et al., 2010). Calcium-imaging exper-
iments demonstrated that cultures of astrocytes reprogrammed
with NEUROG2 are even capable of generating networks of
spontaneously active neurons (Heinrich et al., 2010; Blum et al.,
2011).
The efficiency of reprogramming astrocytes into GABAergic
neurons using MASH1 or DLX2 (∼35%) is lower than into glu-
tamatergic neurons using NEUROG2 (Berninger et al., 2007;
Heinrich et al., 2010). Nevertheless, neurons reprogrammed from





FIGURE 1 | Direct conversion of astrocytes into neurons in vitro.
(A–D) Culture of astrocytes isolated from the postnatal cerebral cortex of
transgenic mice expressing green fluorescent protein (GFP) under the
control of the astrocyte-specific promoter hGFAP (Nolte et al., 2001).
Astrocytes were transduced with NEUROG2 2 h after plating and processed
for immunocytochemistry after 7 days using antibodies against GFP
(green, A and D), NEUROG2 (white, C and D) and the neuronal marker TUJ1
(red, B and D). Observe that astrocytes transduced with NEUROG2 (three
of these cells are highlighted with arrows) adopted a neuronal phenotype,
but still express residual levels of GFP, indicating their astrocytic origin.
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autaptic responses with slow decay time kinetics which are abol-
ished by the GABAA receptor antagonist and show spontaneous
synaptic currents exhibiting a slow decay time, characteristic
of GABAergic current (Heinrich et al., 2010), indicating that
astrocytes are converted to functional GABAergic neurons. Co-
expression of MASH1 and DLX2 in postnatal astrocytes increased
the rate of neuronal conversion up to 90% (Heinrich et al.,
2010), showing that the efficiency to reprogram astrocytes into
GABAergic neurons can be drastically improved by combining
two TFs. Taken together, these data clearly indicate that astro-
cytes can be efficiently converted to functional glutamatergic or
GABAergic neurons through simple molecular manipulations.
REPROGRAMMING OF POSTNATAL ASTROCYTES INTO
DOPAMINERGIC NEURONS
Postnatal cortical astrocytes can also be reprogrammed into
dopaminergic neurons, although this requires a more complex
set of TFs (Addis et al., 2011). Astrocytes-transduced with a poly-
cistronic lentiviral vector encoding for MASH1, LIM homeobox
TF 1 (LMX1), and nuclear receptor related 1 protein (NURR1)
differentiate into neurons expressing biochemical and electro-
physiological characteristics analogous with midbrain dopamin-
ergic neurons. However, the efficiency of astrocyte conversion to
dopaminergic neurons (∼18%) ismuch lower than that described
previously for glutamatergic and GABAergic neurons (Heinrich
et al., 2010; Addis et al., 2011). Yet, the finding that astrocytes
isolated from a region that normally do not generate dopamin-
ergic neurons can be reprogrammed into these types of neurons
using few TFs reveals the great plasticity of astrocytes and sup-
ports the notion that these cells are good candidates to replace
distinct types of neurons in damaged brain areas.
ASTROCYTES IN THE ADULT BRAIN RESUME
PROLIFERATION AND ACQUIRE NEUROGENIC POTENTIAL
AFTER LESION
Astrocytes account for up to one-fifth of the dividing cells in the
first 7 days following traumatic or ischemic brain injury (Buffo
et al., 2005) and at least part of these cells are mature astro-
cytes that resume proliferation after lesion (Buffo et al., 2008).
These reactive, proliferating astrocytes acquire some neural stem
cell-like properties after injury (Buffo et al., 2008; Robel et al.,
2011) and are suitable to reprogramming into functional neurons
(Heinrich et al., 2010).
Although astrocyte activation may play beneficial roles at early
time-points after stroke, there is convincing evidence that astro-
cytes in the glial scar are detrimental for regeneration of the adult
brain (Pekny and Nilsson, 2005; Robel et al., 2011). For instance,
attenuation of reactive gliosis through genetic deletion of inter-
mediate filaments (IFs) glial fibrillary acidic protein (GFAP) and
vimentin in animals subjected to traumatic brain injury improved
regeneration, with a positive effect on complete synaptic restora-
tion (Wilhelmsson et al., 2004). In these same models, neuronal
differentiation and dendritic growth of transplanted cells were
enhanced after transplantation, indicating that reactive gliosis
adversely affects integration of neuronal cells (Widestrand et al.,
2007). In an opposite direction, increasing reactive gliosis worsens
brain injuries, as demonstrated by the finding that overexpression
of S100b, an astrocyte-derived protein, enlarged infarct size and
impaired neurological outcome after ischemia (Mori et al., 2008).
Therefore, reprogramming of astrocytes in the glial scar could per
se improve neurological functions after stroke.
In an ideal scenario, we should be able to find a balance
between diminishing the number of detrimental astrocytes in the
glial scar through reprogramming of these cells into neurons and,
at the same time, conserve non-reprogrammed astrocytes that
could contribute to create an appropriate environment for the
development and functioning of new synaptic contacts between
reprogrammed neurons and the pre-existing circuitry (Wang and
Bordey, 2008). To this point, it is unclear whether reactive astro-
cytes acquiring stem cell-like properties after injury represent a
sobpopulation of astrocytes and what would be the role of such
cells in the glial scar. Future studies should help to clarify this
point and indicate methods to target specific subpopulations of
astrocytes to reprogramming.
REPROGRAMMING OF HUMAN ASTROCYTES INTO
NEURONS
An important question toward translation of astrocyte repro-
gramming into clinic would be whether human astrocytes possess
the same potential to be reprogrammed into neurons. A partial
answer to this question has been recently published in a paper
from Corti et al. (2012). By cultivating astrocytes from the human
cerebral cortex and inducing the expression of TFs involved
in pluripotency (Takahashi and Yamanaka, 2006; Wernig et al.,
2007), the authors could show that astrocytes expressing OCT4,
SOX2, or NANOG generated colonies of neural stem cells (Corti
et al., 2012). These colonies could be expanded and differentiated
into the three major neural cell types—neurons, astrocytes, and
oligodendrocytes (Corti et al., 2012). Neurons expressed typical
neuronal proteins, such as MAP2, synapsin and GABA, suggest-
ing that human astrocytes could be reprogrammed into neurons
acquiring part of the machinery to establish synaptic contacts.
Expression of MASH1 in NSCs derived from human astrocytes
significantly increased the frequency of neuronal differentiation
(Corti et al., 2012), further supporting the key role of neurogenic
determinants to convert astrocytes into neurons.
Strikingly, human astrocytes transduced with NANOG and
transplanted in the lateral ventricles of immunosuppressed mice
survived and integrated into the host brains 2 months after
delivery. Some transplanted cells expressed MAP2 and displayed
complex and long neuritic extensions, compatible with neuronal
differentiation (Corti et al., 2012). Thus, human astrocytes can be
efficiently reprogrammed into neurons both in vitro and in vivo.
Noteworthy, neuronal conversion of human astrocytes occurred
without regression to a pluripotent state, what could contribute
to avoid some complications linked to that state, including the
risk of malignancy.
REPROGRAMMING OF ASTROCYTES INTO
SUBTYPE-SPECIFIC NEURONS
The adult human brain harbors a large variety of neu-
ronal cell types, each exhibiting specific structural, molecular,
and functional features (DeFelipe, 1993; Douglas and Martin,
2004; Markram et al., 2004; Klausberger and Somogyi, 2008).
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Therefore, one important step toward the clinical translation of
astrocyte reprogramming as a therapy for stroke would be to
direct the specification of defined neuronal subtypes. It remains
to be evaluated, for instance, whether astrocytes reprogrammed
by forced expression of NEUROG2 will generate principal and
local glutamatergic neurons of different cortical layers. Similarly,
it is unclear whether GABAergic neurons generated from astro-
cytes reprogrammed with MASH1, DLX2, or combination of
these two TFs will adopt distinct morphological and electrophys-
iological properties, contributing to generate distinct subtypes
of GABAergic interneurons, such as basket and chandelier cells
(Markram et al., 2004) (Figure 2). These questions can only be
answered by experiments assessing the differentiation of neurons
reprogrammed from astrocytes in vivo, either by expressing neu-
rogenic TFs in astrocytes directly in the brain or transplanting
astrocytes previously transduced with neurogenic TFs in vitro
into the healthy or injured brain. Such experiments will allow the
evaluation of neuronal morphology, connectivity and synaptic
formation adopted by reprogrammed astrocytes exposed to the
brain environment.
Nevertheless, data from studies unraveling the molecular
machinery responsible for the generation of neuronal diversity
during development may help to suggest strategies to repro-
gram astrocytes into specific subtypes of neurons. In the last
decade, several works have contributed to identify the genetic
machinery involved in the specification of distinct populations of
cortical glutamatergic neurons (Arlotta et al., 2005; Molyneaux
et al., 2007; Leone et al., 2008). For example, family zinc finger
2 (FEZF2) is necessary for the specification of subcerebral pro-
jection neurons (Chen et al., 2005a,b; Molyneaux et al., 2005),
whereas SATB homeobox 2 (SATB2) is required for proper spec-
ification of callosal projection neurons (Alcamo et al., 2008).
It is tempting to speculate that co-expression of NEUROG2
and FEZF2 or SATB2 in astrocytes would drive reprogrammed
neurons into subcerebral and callosal projection neurons, respec-
tively (Figure 2). In accordance with this possibility, expression of
FEZF2 in striatal progenitors during development is sufficient to
generate cortifugal neurons (Rouaux and Arlotta, 2011).
Similarly, subtypes of cortical GABAergic interneurons origi-
nate from separate progenitor domains characterized by expres-
sion of distinct sets of TFs (Wonders and Anderson, 2006;
Hernandez-Miranda et al., 2010). For instance, parvalbumine-
expressing basket cells originate from progenitors in the medial
ganglionic eminence that express the TFs NK2 homeobox 1
(NKX2.1) and LIM homeobox 6 (LHX6), whereas calretinin-
expressing interneurons originate from the caudal ganglionic
eminence areas that do not express NKX2.1 (Wonders and
Anderson, 2006; Hernandez-Miranda et al., 2010). Therefore, it
is also feasible that distinct subsets of cortical GABAergic neu-
rons could be generated from astrocytes through the expression
of specific combinations of TFs (Figure 2).
TARGETING ASTROCYTES FOR REPROGRAMMING in vivo
Finally, for future clinical approaches, two additional points
remain to be elucidated. The first is how to target specifically



















FIGURE 2 | Direct reprogramming of astrocytes into subtype specific
neurons. Astrocytes can be converted into glutamatergic neurons by
forced expression of NEUROG2 and into GABAergic neurons following
expression of DLX2 and MASH1 (filled arrows). Up to now, it is
unknown which subtype of glutamatergic and GABAergic will be
generated in vivo. We suggest that co-expression of additional TFs,
such as FEZF2, SATB2 or NKX2.1/LHX6, could contribute to generate
more specific subtypes of neurons such as subcerebral projection
neurons, callosal projection neurons or basket cells, respectively
(dashed arrows).
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astrocytic populations. The second point is how to deliver repro-
gramming factors to astrocytes in vivo. As we discussed above,
techniques to convert astrocytes into neurons rely on genetic
manipulations of the cells, which may cause unexpected genetic
modifications (Yamanaka, 2007). One possible way to circum-
vent the need to introduce exogenous genes in astrocytes could
be the use of recombinant proteins. This has been done to con-
vert fibroblasts into induced pluripotent stem cells (Zhou et al.,
2009) and it is likely to work in astrocytes. Another possibility
would be the use of molecules capable of modifying extracellular
signals involved in cell specification. Kondo and Raff (2000), for
instance, have shown that oligodendrocytes precursor cells iso-
lated from the optic nerve and cultured sequentially in platelet
derived growth factor (PDGF), fetal calf serum (FCS), and basic
fibroblast growth factor (bFGF), could revert to a multipotent
neural stem cell state and differentiate into neurons (Kondo and
Raff, 2000). It is tempting to speculate that pharmacological
manipulations of the extracellular milieu or use of recombinant
proteins could substitute DNA elements needed for reprogram-
ming of astrocytes in the glial scar and, therefore, represent a safe
strategy to replace neurons in human patients after stroke.
CONCLUSIONS
Reprogramming of astrocytes in the glial scar into neurons is a
promising approach toward regeneration of nervous tissue after
stroke. In contrast to stem cell transplantation and recruitment
of neural stem cells from neurogenic regions in the adult brain,
parenchymal astrocytes possess the advantage of being present in
large amounts around the lesion. Moreover, conversion of reac-
tive astrocytes into neurons would not only contribute to replace
neuronal populations lost but also help to create an environment
more suitable for neuronal growth and synaptic integration.
Future studies should clarify the potential of reprogrammed
astrocytes to generate different subtypes of neurons in vivo, as
well as identify the subpopulations of astrocytes more suitable
to reprogramming after stroke. Simultaneously, TFs networks
capable of reprogramming astrocytes into specific subtypes of
neurons should be identified, contributing to designmore sophis-
ticated approaches to selectively replace neuronal populations lost
after stroke.
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